ERAP1 and neoplasm: At 46 days post injection all control mice were dead, whereas 60% of sgE-1 tumor-bearing mice were alive (Fig. 5C and Supplementary Figure S9B), suggesting that loss of ERAP1 renders 9464D tumors responsive to entinostat treatment.